Engineered immune cells take on tough childhood leukemia in new trial
NCT ID NCT03573700
First seen Nov 18, 2025 · Last updated May 09, 2026 · Updated 26 times
Summary
This study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. SJCAR19 is made by taking a patient's own immune cells, engineering them in a lab to better recognize and kill cancer cells, and then giving them back. The trial aims to find the safest dose, measure how long the cells last, check side effects, and see if the treatment can put the leukemia into remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.